Cargando…

Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials

INTRODUCTION: Catecholamines are the most used vasopressors in vasodilatory shock. However, the development of adrenergic hyposensitivity and the subsequent loss of catecholamine pressor activity necessitate the search for other options. Our aim was to evaluate the effects of vasopressin and its ana...

Descripción completa

Detalles Bibliográficos
Autores principales: Serpa Neto, Ary, Nassar, Antônio P, Cardoso, Sérgio O, Manetta, José A, Pereira, Victor GM, Espósito, Daniel C, Damasceno, Maria CT, Russell, James A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580743/
https://www.ncbi.nlm.nih.gov/pubmed/22889256
http://dx.doi.org/10.1186/cc11469
_version_ 1782260320944783360
author Serpa Neto, Ary
Nassar, Antônio P
Cardoso, Sérgio O
Manetta, José A
Pereira, Victor GM
Espósito, Daniel C
Damasceno, Maria CT
Russell, James A
author_facet Serpa Neto, Ary
Nassar, Antônio P
Cardoso, Sérgio O
Manetta, José A
Pereira, Victor GM
Espósito, Daniel C
Damasceno, Maria CT
Russell, James A
author_sort Serpa Neto, Ary
collection PubMed
description INTRODUCTION: Catecholamines are the most used vasopressors in vasodilatory shock. However, the development of adrenergic hyposensitivity and the subsequent loss of catecholamine pressor activity necessitate the search for other options. Our aim was to evaluate the effects of vasopressin and its analog terlipressin compared with catecholamine infusion alone in vasodilatory shock. METHODS: A systematic review and meta-analysis of publications between 1966 and 2011 was performed. The Medline and CENTRAL databases were searched for studies on vasopressin and terlipressin in critically ill patients. The meta-analysis was limited to randomized controlled trials evaluating the use of vasopressin and/or terlipressin compared with catecholamine in adult patients with vasodilatory shock. The assessed outcomes were: overall survival, changes in the hemodynamic and biochemical variables, a decrease of catecholamine requirements, and adverse events. RESULTS: Nine trials covering 998 participants were included. A meta-analysis using a fixed-effect model showed a reduction in norepinephrine requirement among patients receiving terlipressin or vasopressin infusion compared with control (standardized mean difference, -1.58 (95% confidence interval, -1.73 to -1.44); P < 0.0001). Overall, vasopressin and terlipressin, as compared with norepinephrine, reduced mortality (relative risk (RR), 0.87 (0.77 to 0.99); P = 0.04). Vasopressin compared with norepinephrine decreased mortality in adult patients (RR, 0.87 (0.76 to 1.00); P = 0.05) and in patients with septic shock (42.5% vs. 49.2%, respectively; RR, 0.87 (0.75 to 1.00); P = 0.05; number needed to treat, 1 to 15). There was no difference in adverse events between the vasopressin and control groups (RR, 0.98 (0.65 to 1.47); P = 0.92). CONCLUSIONS: Vasopressin use in vasodilatory shock is safe, associated with reduced mortality, and facilitates weaning of catecholamines. In patients with septic shock, use of vasopressin compared with norepinephrine may also decrease mortality.
format Online
Article
Text
id pubmed-3580743
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35807432013-02-26 Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials Serpa Neto, Ary Nassar, Antônio P Cardoso, Sérgio O Manetta, José A Pereira, Victor GM Espósito, Daniel C Damasceno, Maria CT Russell, James A Crit Care Research INTRODUCTION: Catecholamines are the most used vasopressors in vasodilatory shock. However, the development of adrenergic hyposensitivity and the subsequent loss of catecholamine pressor activity necessitate the search for other options. Our aim was to evaluate the effects of vasopressin and its analog terlipressin compared with catecholamine infusion alone in vasodilatory shock. METHODS: A systematic review and meta-analysis of publications between 1966 and 2011 was performed. The Medline and CENTRAL databases were searched for studies on vasopressin and terlipressin in critically ill patients. The meta-analysis was limited to randomized controlled trials evaluating the use of vasopressin and/or terlipressin compared with catecholamine in adult patients with vasodilatory shock. The assessed outcomes were: overall survival, changes in the hemodynamic and biochemical variables, a decrease of catecholamine requirements, and adverse events. RESULTS: Nine trials covering 998 participants were included. A meta-analysis using a fixed-effect model showed a reduction in norepinephrine requirement among patients receiving terlipressin or vasopressin infusion compared with control (standardized mean difference, -1.58 (95% confidence interval, -1.73 to -1.44); P < 0.0001). Overall, vasopressin and terlipressin, as compared with norepinephrine, reduced mortality (relative risk (RR), 0.87 (0.77 to 0.99); P = 0.04). Vasopressin compared with norepinephrine decreased mortality in adult patients (RR, 0.87 (0.76 to 1.00); P = 0.05) and in patients with septic shock (42.5% vs. 49.2%, respectively; RR, 0.87 (0.75 to 1.00); P = 0.05; number needed to treat, 1 to 15). There was no difference in adverse events between the vasopressin and control groups (RR, 0.98 (0.65 to 1.47); P = 0.92). CONCLUSIONS: Vasopressin use in vasodilatory shock is safe, associated with reduced mortality, and facilitates weaning of catecholamines. In patients with septic shock, use of vasopressin compared with norepinephrine may also decrease mortality. BioMed Central 2012 2012-08-14 /pmc/articles/PMC3580743/ /pubmed/22889256 http://dx.doi.org/10.1186/cc11469 Text en Copyright ©2012 Serpa Neto et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Serpa Neto, Ary
Nassar, Antônio P
Cardoso, Sérgio O
Manetta, José A
Pereira, Victor GM
Espósito, Daniel C
Damasceno, Maria CT
Russell, James A
Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials
title Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials
title_full Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials
title_fullStr Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials
title_full_unstemmed Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials
title_short Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials
title_sort vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580743/
https://www.ncbi.nlm.nih.gov/pubmed/22889256
http://dx.doi.org/10.1186/cc11469
work_keys_str_mv AT serpanetoary vasopressinandterlipressininadultvasodilatoryshockasystematicreviewandmetaanalysisofninerandomizedcontrolledtrials
AT nassarantoniop vasopressinandterlipressininadultvasodilatoryshockasystematicreviewandmetaanalysisofninerandomizedcontrolledtrials
AT cardososergioo vasopressinandterlipressininadultvasodilatoryshockasystematicreviewandmetaanalysisofninerandomizedcontrolledtrials
AT manettajosea vasopressinandterlipressininadultvasodilatoryshockasystematicreviewandmetaanalysisofninerandomizedcontrolledtrials
AT pereiravictorgm vasopressinandterlipressininadultvasodilatoryshockasystematicreviewandmetaanalysisofninerandomizedcontrolledtrials
AT espositodanielc vasopressinandterlipressininadultvasodilatoryshockasystematicreviewandmetaanalysisofninerandomizedcontrolledtrials
AT damascenomariact vasopressinandterlipressininadultvasodilatoryshockasystematicreviewandmetaanalysisofninerandomizedcontrolledtrials
AT russelljamesa vasopressinandterlipressininadultvasodilatoryshockasystematicreviewandmetaanalysisofninerandomizedcontrolledtrials